{"id":"ak104-lenvatinib","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Hypertension"},{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Weight loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these receptors, AK104 lenvatinib reduces tumor angiogenesis and growth. This mechanism is similar to other lenvatinib-based treatments.","oneSentence":"AK104 lenvatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:34.737Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic renal cell carcinoma"},{"name":"Papillary thyroid carcinoma"}]},"trialDetails":[{"nctId":"NCT05824481","phase":"PHASE2","title":"Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-08","conditions":"Endometrial Cancer, Endometrial Adenocarcinoma","enrollment":32},{"nctId":"NCT06361758","phase":"PHASE2","title":"Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC","status":"WITHDRAWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-05-31","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT06984718","phase":"PHASE2","title":"A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2025-06-25","conditions":"HCC, Hepatocellular Carcinoma","enrollment":120},{"nctId":"NCT05319431","phase":"PHASE2","title":"A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-06-28","conditions":"Unresectable, Non-metastatic Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT06371157","phase":"PHASE3","title":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-08-02","conditions":"Hepatocellular Carcinoma","enrollment":469},{"nctId":"NCT06035224","phase":"PHASE2","title":"A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-08-23","conditions":"Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy","enrollment":28},{"nctId":"NCT06406634","phase":"PHASE2","title":"Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2024-05-15","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT04728321","phase":"PHASE2","title":"A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-01-27","conditions":"Hepatocellular Carcinoma","enrollment":32},{"nctId":"NCT04444167","phase":"PHASE1, PHASE2","title":"A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Akeso","startDate":"2020-07-07","conditions":"Hepatocellular Carcinoma","enrollment":59},{"nctId":"NCT06215651","phase":"PHASE2","title":"Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-03-11","conditions":"Cadonilimab and Lenvatinib","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AK104 lenvatinib","genericName":"AK104 lenvatinib","companyName":"Akeso","companyId":"akeso","modality":"Biologic","firstApprovalDate":"","aiSummary":"AK104 lenvatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR). Used for Metastatic renal cell carcinoma, Papillary thyroid carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}